Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2013

Open Access 01-12-2013 | Study protocol

The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: study protocol for a pilot randomised controlled trial with embedded process evaluation

Authors: Mariyana Schoultz, Iain M Atherton, Gill Hubbard, Angus JM Watson

Published in: Trials | Issue 1/2013

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) is a chronic condition with an unpredictable disease course. Rates of anxiety and depression among IBD patients in relapse (active disease symptoms) as well as in remission are higher than in the general population. Previous studies suggest that the prolonged effect of pain, anxiety, distress and depression have a detrimental effect on patients’quality of life (QoL). Poor QoL in itself is associated with further symptom relapse. Mindfulness based cognitive therapy (MBCT) is a psychological group intervention that has the potential to improve QoL. When used in other chronic conditions, it demonstrated reduced negative effect from pain and psychological factors at completion of an 8-week MBCT course. The effect of MBCT has never been researched in IBD. The aim of this study is to obtain the information required to design a full scale randomised controlled trial (RCT) that will examine the effectiveness of MBCT in improving quality of life for IBD patients.

Methods/Design

This is an exploratory RCT with embedded process evaluation. Forty IBD patients will be recruited from NHS outpatient gastroenterology clinics and will be randomised to either a MBCT (intervention) group or to a wait-list (control) group. All participants will undergo 16 h of structured group training over an 8-week period, with the control group starting 6 months later than the intervention group. Primary outcomes are recruitment, completion/retention rates and adherence and adaptation to the MBCT manual for IBD patients. The secondary outcome is to assess the feasibility of collecting reliable and valid data on proposed outcome measures such as quality of life, anxiety, depression, disease activity and mindful awareness. The process evaluation will use a survey and focus groups to assess the acceptability of the intervention and trial procedures for IBD patients.

Discussion

The outcomes of this study will help define the barriers, uptake and perceived benefits of MBCT program for IBD patients. This information will enable the design of a full-scale study assessing the effect of MBCT on quality of life for IBD patients.

Trial registration

Current Controlled Trials: ISRCTN27934462
Appendix
Available only for authorised users
Literature
1.
Casati J, Toner B: Psychosocial aspects of inflammatory bowel disease. Biomed Pharmacother. 2000, 54: 388-393. 10.1016/S0753-3322(01)80006-8.CrossRefPubMed
2.
Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007, 369: 1641-1657. 10.1016/S0140-6736(07)60751-X.CrossRefPubMed
3.
Baumgart DC, Sandborn WJ: Crohn’s disease. Lancet. 2012, 380: 1590-1605. 10.1016/S0140-6736(12)60026-9.CrossRefPubMed
4.
Head KA, Jurenka JS: Inflammatory bowel disease part 1: ulcerative colitis–pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003, 8: 247-283.PubMed
5.
Stone MA, Mayberry JF, Baker R: Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol. 2003, 15: 1275-1280. 10.1097/00042737-200312000-00004.CrossRefPubMed
6.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012, 142: 46-54. 10.1053/j.gastro.2011.10.001.CrossRefPubMed
7.
Johnson M, Lithgo K, Prouse T, Price T: PWE-095 A 10 year review of the death rate and cause of death within a district general cohort of inflammatory bowel disease patients. Gut. 2013, Suppl 1: A169-
8.
Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J: The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006, 4: 1491-1501. 10.1016/j.cgh.2006.09.027. e1CrossRefPubMed
9.
Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G: Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004, 66: 79-84. 10.1097/01.PSY.0000106907.24881.F2.CrossRefPubMed
10.
Graff LA, Walker JR, Bernstein CN: Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009, 15: 1105-1118. 10.1002/ibd.20873.CrossRefPubMed
11.
Faust AH, Halpern LF, Danoff-Burg S, Cross RK: Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life. Gastroenterol Hepatol. 2012, 8: 173-
12.
Levenstein S: Embracing complexity: what determines quality of life in inflammatory bowel disease?. Eur J Gastroenterol Hepatol. 2004, 16: 1253-1255. 10.1097/00042737-200412000-00002.CrossRefPubMed
13.
Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES: Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002, 97: 389-396.CrossRefPubMed
14.
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ: Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Mental Health. 2006, 2: 24-10.1186/1745-0179-2-24.CrossRef
15.
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ: “It doesn’t do any harm, but patients feel better”: a qualitative exploratory study on gastroenterologists’ perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol. 2007, 7: 38-10.1186/1471-230X-7-38.CrossRefPubMedPubMedCentral
16.
Goodhand JR, Greig FIS, Koodun Y, McDermott A, Wahed M, Langmead L, Rampton DS: Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis. 2012, 18: 1232-1239. 10.1002/ibd.21846.CrossRefPubMed
17.
Pacher P, Kecskemeti V: Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des. 2004, 10: 2463-10.2174/1381612043383872.CrossRefPubMedPubMedCentral
18.
Andersohn F, Schade R, Suissa S, Garbe E: Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009, 166: 591-598. 10.1176/appi.ajp.2008.08071065.CrossRefPubMed
19.
Makins R, Ballinger A: Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003, 2: 421-429. 10.1517/14740338.2.4.421.CrossRefPubMed
20.
Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A: Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010, 16: 3168-10.3748/wjg.v16.i25.3168.CrossRefPubMedPubMedCentral
21.
Bernal I, Domenech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, Cabré E, Gassull MA: Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006, 51: 2165-2169. 10.1007/s10620-006-9444-2.CrossRefPubMed
22.
Jackson C, Clatworthy J, Robinson A, Horne R: Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2009, 105: 525-539.CrossRefPubMed
23.
Segal ZV, Williams J, Teasdale JD: Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse. 2002, New York, NY: The Guilford Press
24.
Kabat-Zinn J: Full catastrophe living: using the wisdom of your body and mind to face stress, pain, and illness. 1990, New York: Bantam Doubleday Dell Publishing
25.
Baer RA: Mindfulness training as a clinical intervention: a conceptual and empirical review. Clin Psychol Sci Pract. 2003, 10: 125-143. 10.1093/clipsy.bpg015.CrossRef
26.
Kabat‒Zinn J: Mindfulness‒based interventions in context: past, present, and future. Clin Psychol Sci Pract. 2003, 10: 144-156. 10.1093/clipsy.bpg016.CrossRef
27.
28.
Rosenzweig S, Greeson JM, Reibel DK, Green JS, Jasser SA, Beasley D: Mindfulness-based stress reduction for chronic pain conditions: Variation in treatment outcomes and role of home meditation practice. J Psychosom Res. 2010, 68: 29-10.1016/j.jpsychores.2009.03.010.CrossRefPubMed
29.
Bohlmeijer E, Prenger R, Taal E, Cuijpers P: The effects of mindfulness-based stress reduction therapy on mental health of adults with a chronic medical disease: a meta-analysis. J Psychosom Res. 2010, 68: 539-544. 10.1016/j.jpsychores.2009.10.005.CrossRefPubMed
30.
Jedel S, Merriman P, Hoffman A, Swanson B, Fogg LF, Keshavarzian A: Relationship of mindfulness, quality of life, and psychiatric symptoms among patients with ulcerative colitis. Mindfulness. 2013, 4: 296-300. 10.1007/s12671-012-0128-z.CrossRef
31.
Segal ZV, Williams JMG, Teasdale JD: Mindfulness-based cognitive therapy for depression. 2012, New York, NY: The Guilford Press, 2
32.
Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH: Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005, Suppl 1: S22-S28.CrossRef
33.
Maunder RG, Esplen MJ: Supportive-expressive group psychotherapy for persons with inflammatory bowel disease. Can J Psychiatr. 2001, 46: 622-626.
34.
Larsson K, Karlbom U, Nordin K, Anderberg U, Lööf L: A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis. Scand J Gastroenterol. 2003, 38: 763-769. 10.1080/00365520310003309.CrossRefPubMed
35.
Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers A, Sculpher M, Thompson D: A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut. 2004, 53: 1639-1645. 10.1136/gut.2003.034256.CrossRefPubMedPubMedCentral
36.
Jäghult S, Larson J, Wredling R, Kapraali M: A multiprofessional education programme for patients with inflammatory bowel disease: a randomized controlled trial. Scand J Gastroenterol. 2007, 42: 1452-1459. 10.1080/00365520701439685.CrossRefPubMed
37.
Sibaja D, Comeche Moreno M, Mas Hesse B: Tratamiento cognitivo-conductual protocolizado en grupo de las enfermedades inflamatorias intestinales. Rev Esp Enferm Dig. 2007, 99: 593-598.
38.
Oxelmark L, Magnusson A, Löfberg R, Hillerås P: Group‒based intervention program in inflammatory bowel disease patients: effects on quality of life. Inflamm Bowel Dis. 2007, 13: 182-190. 10.1002/ibd.20061.CrossRefPubMed
39.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M: Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008, 337: a1655-10.1136/bmj.a1655.CrossRefPubMedPubMedCentral
40.
McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I: What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006, 7: 9-10.1186/1745-6215-7-9.CrossRefPubMedPubMedCentral
41.
Caldwell PH, Hamilton S, Tan A, Craig JC: Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med. 2010, 7: e1000368-10.1371/journal.pmed.1000368.CrossRefPubMedPubMedCentral
42.
43.
Burgess D, Gebski V, Keech A: EBM: trials on trial. Med J Aust. 2003, 179: 105-107.PubMed
44.
Gaylord SA, Palsson OS, Garland EL, Faurot KR, Coble RS, Mann JD, Frey W, Leniek K, Whitehead WE: Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol. 2011, 106: 1678-1688. 10.1038/ajg.2011.184.CrossRefPubMed
45.
Wells CW, Lewis S, Barton JR, Corbett S: Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006, 12: 123-130. 10.1097/01.MIB.0000196646.64615.db.CrossRefPubMed
46.
Guyatt G, Mitchell A, Irvine E, Singer J, Williams N, Goodacre R, Tompkins C: A new measure of health status for clinical trials in inflammatory bowel. Gastroenterology. 1989, 96: 804-810.CrossRefPubMed
47.
Lix LM, Graff LA, Walker JR, Clara I, Rawsthorne P, Rogala L, Miller N, Ediger J, Pretorius T, Bernstein CN: Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008, 14: 1575-1584. 10.1002/ibd.20511.CrossRefPubMed
48.
Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory. 1983, Palo Alto, CA: Consulting Psychologists Press
49.
Beck AT, Steer RA, Carbin MG: Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988, 8: 77-100. 10.1016/0272-7358(88)90050-5.CrossRef
50.
Akbar A, Yiangou Y, Facer P, Brydon W, Walters JR, Anand P, Ghosh S: Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010, 59: 767-774. 10.1136/gut.2009.194449.CrossRefPubMed
51.
Goebell H, Wienbeck M, Schomerus H, Malchow H: Evaluation of the Crohn’s Disease Activity Index (CDAI) and the Dutch index for severity and activity of Crohn’s disease. An analysis of the data from the European Cooperative Crohn’s Disease Study. Med Klinik (Munich). 1990, 85: 573-576.
52.
Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Färkkilä M: Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008, 14: 40-46. 10.1002/ibd.20312.CrossRefPubMed
53.
54.
Carlson LE, Brown KW: Validation of the mindful attention awareness scale in a cancer population. J Psychosom Res. 2005, 58: 29-33. 10.1016/j.jpsychores.2004.04.366.CrossRefPubMed
55.
MacKillop J, Anderson EJ: Further psychometric validation of the mindful attention awareness scale (MAAS). J Psychopathol Behav Assess. 2007, 29: 289-293. 10.1007/s10862-007-9045-1.CrossRef
56.
Hertzog MA: Considerations in determining sample size for pilot studies. Res Nurs Health. 2008, 31: 180-191. 10.1002/nur.20247.CrossRefPubMed
57.
Johanson GA, Brooks GP: Initial scale development: sample size for pilot studies. Educ Psychol Meas. 2010, 70: 394-400. 10.1177/0013164409355692.CrossRef
58.
Crane C, Williams JMG: Factors associated with attrition from mindfulness-based cognitive therapy in patients with a history of suicidal depression. Mindfulness. 2010, 1: 10-20. 10.1007/s12671-010-0003-8.CrossRefPubMedPubMedCentral
59.
Ritchie J, Spencer L: Qualitative data analysis for applied policy research. Analysing qualitative data. Edited by: Bryman A, Burgess R. 1993, London: Routledge, 173-194.
Metadata
Title
The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: study protocol for a pilot randomised controlled trial with embedded process evaluation
Authors
Mariyana Schoultz
Iain M Atherton
Gill Hubbard
Angus JM Watson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Trials / Issue 1/2013
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-14-431

Other articles of this Issue 1/2013

Trials 1/2013 Go to the issue

Research

Challenges for consent and community engagement in the conduct of cluster randomized trial among school children in low income settings: experiences from Kenya

Update

Update on the collaborative interventions for circulation and depression (COINCIDE) trial: changes to planned methodology of a cluster randomized controlled trial of collaborative care for depression in people with diabetes and/or coronary heart disease

Study protocol

Comparison of three different dressings for partial thickness burns in children: study protocol for a randomised controlled trial

Study protocol

Sentinel node in ovarian cancer: study protocol for a phase 1 study

Study protocol

Efficacy and safety of acupuncture for chronic dizziness: study protocol for a randomized controlled trial

Study protocol

Evaluation of the effectiveness and cost-effectiveness of Families for Health V2 for the treatment of childhood obesity: study protocol for a randomized controlled trial